PYPD Stock Analysis: Buy, Sell, or Hold?
PYPD - PolyPid Ltd. Ordinary Shares
$4.62
0.05 (1.09%)
▲
5d:
+2.67%
30d:
+9.48%
90d:
+10.26%
BUY
HIGH Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When PYPD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PYPD shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PYPD shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: PYPD is currently trading at $4.62, which is considered fair relative to its 30-day fair value range of $4.43 to $4.85.
Technical Outlook: Technically, PYPD is in a uptrend. Immediate support is located at $4.40, while resistance sits at $5.21.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.25 (+165.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PYPD is in a uptrend. Immediate support is located at $4.40, while resistance sits at $5.21.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.25 (+165.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.43 -
$4.85
Company Quality Score
53/100
(HOLD)
Options IV Signal
6th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 6th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 165.2% below Wall St target ($12.25)
Trading Range Analysis
30-Day Trading Range
$4.43 -
$4.85
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.79
(17.0%)
Support & Resistance Levels
Support Level
$4.40
Resistance Level
$5.21
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.68
Wall Street Target
$12.25
(+165.2%)
Share & Embed Analysis
Last updated: June 13, 2026 10:52 AM ET
Data refreshes hourly during market hours. Next update: 11:52 AM
Data refreshes hourly during market hours. Next update: 11:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PYPD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 58 HOLD |
